GlassScriptPhysician profile
Kayla Davis
NPI 1407529100
$1,186.65
in general payments reported to CMS, 2019-2025
24 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $117 · 2022: $145 · 2023: $197 · 2024: $356 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $925.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $924.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $334.77 | 2024-2025 | Reblozyl, Abecma |
| Corium, LLC | $112.65 | 2021-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $78.61 | 2025 | Jornay Pm |
| Janssen Pharmaceuticals, INC | $66.36 | 2023-2024 | Spravato |
| Pfizer INC. | $64.25 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $57.21 | 2023-2025 | Airsupra, Flumist Quadrivalent |
| Cvrx, INC. | $50.33 | 2025 | Barostim Neo System |
| Novartis Pharmaceuticals Corporation | $48.81 | 2022-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.92 | 2022-2025 | |
| Novo Nordisk INC | $39.63 | 2024-2025 | Wegovy |
| Abbvie INC. | $29.66 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $29.49 | 2022-2024 | Rotateq, Gardasil, Gardasil 9 |
| Sanofi Pasteur INC. | $28.23 | 2023 | |
| Glaxosmithkline, LLC. | $27.37 | 2022-2023 | Arexvy, Shingrix |
| Axsome Therapeutics, INC. | $24.74 | 2024 | Auvelity |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verrica Pharmaceuticals INC. | $23.29 | 2024 | Ycanth |
| Idorsia Pharmaceuticals US INC | $19.97 | 2023 | Quviviq |
| Soleno Therapeutics, INC. | $18.13 | 2025 | Vykat Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $17.97 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $17.52 | 2021 | |
| Genentech USA, INC. | $17.43 | 2021 | |
| Ironshore Pharmaceuticals INC. | $16.18 | 2021 | |
| Lilly USA, LLC | $12.45 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $11.68 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kayla Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.